- |||||||||| uzansertib (INCB53914) / Incyte
Trial termination, Metastases: Study of INCB053914 in Subjects With Advanced Malignancies (clinicaltrials.gov) - Dec 8, 2021
P1/2, N=97, Terminated,
Future studies are needed to identify rational, effective combination strategies. Completed --> Terminated
- |||||||||| uzansertib (INCB53914) / Incyte
Trial completion, Trial completion date, Trial primary completion date, Metastases: Study of INCB053914 in Subjects With Advanced Malignancies (clinicaltrials.gov) - Apr 8, 2021
P1/2, N=97, Completed,
Completed --> Terminated Active, not recruiting --> Completed | Trial completion date: Jan 2021 --> Jul 2020 | Trial primary completion date: Jan 2021 --> Jul 2020
- |||||||||| Jakafi oral (ruxolitinib) / Novartis, Incyte, uzansertib (INCB53914) / Incyte
Journal, Combination therapy: The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN. (Pubmed Central) - Sep 9, 2020
Significantly, low nanomolar INCB053914 enhances the efficacy of ruxolitinib to inhibit the neoplastic growth of primary MPN patient cells, and INCB053914 antagonizes ruxolitinib persistent myeloproliferation in vivo. These findings support the notion that INCB053914, which is currently in clinical trials in patients with advanced hematologic malignancies, in combination with ruxolitinib may be effective in MPN patients, and they support the clinical testing of this combination in MPN patients.
- |||||||||| uzansertib (INCB53914) / Incyte
Enrollment change, Trial completion date, Trial initiation date, Trial withdrawal, Trial primary completion date: INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Aug 19, 2020
P1, N=0, Withdrawn,
These findings support the notion that INCB053914, which is currently in clinical trials in patients with advanced hematologic malignancies, in combination with ruxolitinib may be effective in MPN patients, and they support the clinical testing of this combination in MPN patients. N=18 --> 0 | Trial completion date: Jul 2023 --> Jul 2024 | Initiation date: Jul 2020 --> Jul 2021 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jul 2022 --> Jul 2023
- |||||||||| uzansertib (INCB53914) / Incyte
Enrollment closed, Enrollment change, Metastases: Study of INCB053914 in Subjects With Advanced Malignancies (clinicaltrials.gov) - Jul 21, 2020
P1/2, N=97, Active, not recruiting,
N=18 --> 0 | Trial completion date: Jul 2023 --> Jul 2024 | Initiation date: Jul 2020 --> Jul 2021 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jul 2022 --> Jul 2023 Recruiting --> Active, not recruiting | N=270 --> 97
- |||||||||| parsaclisib (INCB50465) / Incyte, uzansertib (INCB53914) / Incyte
Enrollment closed, Enrollment change, Combination therapy: A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Jul 21, 2020
P1b, N=9, Active, not recruiting,
Recruiting --> Active, not recruiting | N=270 --> 97 Recruiting --> Active, not recruiting | N=25 --> 9
- |||||||||| uzansertib (INCB53914) / Incyte
Trial completion date, Trial primary completion date, Metastases: Study of INCB053914 in Subjects With Advanced Malignancies (clinicaltrials.gov) - Mar 5, 2020
P1/2, N=270, Recruiting,
Recruiting --> Active, not recruiting | N=25 --> 9 Trial completion date: Jan 2020 --> Jan 2021 | Trial primary completion date: Jan 2020 --> Jan 2021
- |||||||||| Abnl Marro: An International Cooperative Trial for Patients with MDS/MPN Overlap Syndromes (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_6016;
This design yields a type I error rate of 0.05 and power of 80% when the true response rate is 55% . The probability of early termination and expected sample size of any arm is 64% and 25 pts, respectively, assuming low (35% RR) efficacy Beyond the primary objectives of the study to evaluate the safety and efficacy of novel treatment combinations in MDS/MPN, the study will establish the ABNL MARRO infrastructure that leverages the expertise of the MDS/MPN international working group (IWG) for future prospective studies; will forge innovative scientific research that will improve our understanding of pathogenetic etiologies; and will inform the clinical application of diagnosis, risk stratification tools, and response assessments in MDS/MPNs.
- |||||||||| JQ-1 / Roche, INCB054329 / Incyte, INCB53914 / Incyte
Bromodomain and Extra Terminal Domain (BET) Inhibitors Sensitize Chronic Myelomonocytic Leukemia (CMML) to PIM Inhibition Via Downregulation of Mir-33a (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_5962;
Surprisingly, we identified that PIM1 was increased following treatment with INCB54329, other BETi, or a JQ1-derived PROTAC (Fig...Consistent with this, isogenic SKM1 leukemia cells engineered to overexpress PIM1 were resistant to INCB54329 and were more sensitive to INCB53914 versus controls cells...Collectively, these studies established BET and PIM inhibition as a novel and potent combination therapy for CMML that is mediated by miR-33a-dependent upregulation of PIM1(Fig . 1E).
- |||||||||| uzansertib (INCB53914) / Incyte
Enrollment change, Trial primary completion date, Metastases: Study of INCB053914 in Subjects With Advanced Malignancies (clinicaltrials.gov) - May 18, 2017
P1/2, N=270, Recruiting,
Not yet recruiting --> Recruiting N=135 --> 270 | Trial primary completion date: Oct 2017 --> Jan 2020
|
